Physician profile
Ryan N Constantine
NPI 1932527199
$5,194.70
in general payments reported to CMS, 2019-2025
12 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,173 · 2020: $23.56 · 2021: $156 · 2022: $404 · 2023: $267 · 2024: $2,018 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,600 · Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,600.00 |
| Food and Beverage | $838.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,726.73 | 2022-2024 | Ozurdex |
| Roche Tcrc, INC. | $1,391.34 | 2019 | |
| Genentech USA, INC. | $772.73 | 2019-2025 | Vabysmo |
| Genentech, INC. | $452.22 | 2022-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $367.51 | 2019-2025 | Eylea, Eylea Hd |
| Alimera Sciences, INC. | $109.17 | 2024 | Yutiq, Iluvien |
| Hoffmann-La Roche Limited | $99.00 | 2019 | |
| Allergan, INC. | $95.75 | 2022 | |
| Astellas Pharma US INC | $79.43 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $64.81 | 2022-2024 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.33 | 2021 | |
| Kala Pharmaceuticals, INC. | $17.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Constantine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.